A Dual Immunotherapy Nanoparticle Improves T-Cell Activation and Cancer Immunotherapy
出版年份 2018 全文链接
标题
A Dual Immunotherapy Nanoparticle Improves T-Cell Activation and Cancer Immunotherapy
作者
关键词
-
出版物
ADVANCED MATERIALS
Volume 30, Issue 25, Pages 1706098
出版商
Wiley
发表日期
2018-04-25
DOI
10.1002/adma.201706098
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Erratum: The future of cancer treatment: immunomodulation, CARs and combination immunotherapy
- (2016) Danny N. Khalil et al. Nature Reviews Clinical Oncology
- Safety profiles of anti-CTLA-4 and anti-PD-1 antibodies alone and in combination
- (2016) Celine Boutros et al. Nature Reviews Clinical Oncology
- Immunoengineering: How Nanotechnology Can Enhance Cancer Immunotherapy
- (2015) Michael S. Goldberg CELL
- Anti–PD-1/PD-L1 therapy of human cancer: past, present, and future
- (2015) Lieping Chen et al. JOURNAL OF CLINICAL INVESTIGATION
- Safety and Antitumor Activity of Anti–PD-1 Antibody, Nivolumab, in Patients With Platinum-Resistant Ovarian Cancer
- (2015) Junzo Hamanishi et al. JOURNAL OF CLINICAL ONCOLOGY
- Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063): a phase 2, single-arm trial
- (2015) Naiyer A Rizvi et al. LANCET ONCOLOGY
- T-cell exhaustion, co-stimulation and clinical outcome in autoimmunity and infection
- (2015) Eoin F. McKinney et al. NATURE
- Radiation and dual checkpoint blockade activate non-redundant immune mechanisms in cancer
- (2015) Christina Twyman-Saint Victor et al. NATURE
- Combination cancer immunotherapy and new immunomodulatory targets
- (2015) Kathleen M. Mahoney et al. NATURE REVIEWS DRUG DISCOVERY
- Nivolumab and Ipilimumab versus Ipilimumab in Untreated Melanoma
- (2015) Michael A. Postow et al. NEW ENGLAND JOURNAL OF MEDICINE
- Pembrolizumab versus Ipilimumab in Advanced Melanoma
- (2015) Caroline Robert et al. NEW ENGLAND JOURNAL OF MEDICINE
- Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma
- (2015) James Larkin et al. NEW ENGLAND JOURNAL OF MEDICINE
- The future of immune checkpoint therapy
- (2015) P. Sharma et al. SCIENCE
- T-cell exhaustion in the tumor microenvironment
- (2015) Y Jiang et al. Cell Death & Disease
- Survival, Durable Tumor Remission, and Long-Term Safety in Patients With Advanced Melanoma Receiving Nivolumab
- (2014) Suzanne L. Topalian et al. JOURNAL OF CLINICAL ONCOLOGY
- Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial
- (2014) Caroline Robert et al. LANCET
- Checkpoint blockade cancer immunotherapy targets tumour-specific mutant antigens
- (2014) Matthew M. Gubin et al. NATURE
- Antigen-specific activation and cytokine-facilitated expansion of naive, human CD8+ T cells
- (2014) Matthias Wölfl et al. Nature Protocols
- Localized Immunotherapy via Liposome-Anchored Anti-CD137 + IL-2 Prevents Lethal Toxicity and Elicits Local and Systemic Antitumor Immunity
- (2013) B. Kwong et al. CANCER RESEARCH
- Regulatory T cells in melanoma: the final hurdle towards effective immunotherapy?
- (2012) Joannes FM Jacobs et al. LANCET ONCOLOGY
- Induction of potent anti-tumor responses while eliminating systemic side effects via liposome-anchored combinatorial immunotherapy
- (2011) Brandon Kwong et al. BIOMATERIALS
- Cancer immunotherapy comes of age
- (2011) Ira Mellman et al. NATURE
- T cell exhaustion
- (2011) E John Wherry NATURE IMMUNOLOGY
- Thiol-click chemistry: a multifaceted toolbox for small molecule and polymer synthesis
- (2010) Charles E. Hoyle et al. CHEMICAL SOCIETY REVIEWS
- Adjuvant Therapy With Agonistic Antibodies to CD134 (OX40) Increases Local Control After Surgical or Radiation Therapy of Cancer in Mice
- (2010) Michael J. Gough et al. JOURNAL OF IMMUNOTHERAPY
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started